LEADER 03473oam  2200613I  450 
001 9910143270803321
005 20230828203409.0
010   $a0-429-12945-9
010   $a1-280-51646-1
010   $a9786610516469
010   $a1-4200-0433-6
024 7 $a10.1201/9781420004335 
035   $a(CKB)1000000000345219
035   $a(EBL)274060
035   $a(OCoLC)476017823
035   $a(SSID)ssj0000103661
035   $a(PQKBManifestationID)11131248
035   $a(PQKBTitleCode)TC0000103661
035   $a(PQKBWorkID)10070328
035   $a(PQKB)11108564
035   $a(MiAaPQ)EBC274060
035   $a(OCoLC)84543420
035   $a(EXLCZ)991000000000345219
100   $a20180331d2006      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAnimal models of cognitive impairment /$fedited by Edward D. Levin, Jerry J. Buccafusco
210  1$aBoca Raton :$cCRC/Taylor & Francis,$d2006.
215   $a1 online resource (395 p.)
225 1 $aFrontiers in neuroscience
300   $aDescription based upon print version of record.
311   $a0-8493-2834-9 
320   $aIncludes bibliographical references and index.
327   $aFront Cover; Preface; About the Editors; Contributors; Contents; List of Illustrations; 1.  Introduction; 2.  Muscarinic Receptor Antagonists in Rats; 3.  Nicotinic Receptor Antagonists in Rats; 4.  Involvement of the NMDA System in Learning and Memory; 5.  Animal Models and the Cognitive Effects of Ethanol; 6.  Animal Models of Cognitive Impairment Produced by Developmental Lead Exposure; 7.  Developmental Behavioral Toxicity of Methylmercury: Consequences, Conditioning, and Cortex
327   $a8.  Executive Function following Developmental Exposure to Polychlorinated Biphenyls (PCBs): What Animal Models Have Told Us9.  Modeling Cognitive Deficits Associated with Parkinsonism in the Chronic-Low-Dose MPTP-Treated Monkey; 10.  Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition; 11.  Cholinergic Receptor Knockout Mice; 12.  Assessments of Cognitive Deficits in Mutant Mice; 13.  Cognitive Pharmacology in Aging Macaques; 14.  Cognitive Impairment following Traumatic Brain Injury; 15.  Cognitive Impairment Models Using Complementary Species
327   $a16.  Cognition Models and Drug DiscoveryIndex
330   $aThe costs associated with a drug's clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.   Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairment examines some of the most popular and successful animal archetypes used in the context of drug discovery. It provides integrated coverage of the latest research concerning neuronal systems relevant to cognitive function and dysfunction, assimi
410  0$aFrontiers in neuroscience (Boca Raton, Fla.)
606   $aCognition disorders$xAnimal models
615  0$aCognition disorders$xAnimal models.
676   $a573.8
676   $a616.8
701   $aLevin$b Edward D$01239726
701   $aBuccafusco$b Jerry J$01236265
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910143270803321
996   $aAnimal models of cognitive impairment$92876263
997   $aUNINA